Pharmaceutical companies are on a dealmaking tear. Six pharma companies have signed acquisitions worth up to $25.5 billion since the beginning of last week. Two $5 billion-plus upfront deals were disclosed on Tuesday morning alone: Eli Lilly’s bet on Centessa Pharmaceuticals’ orexins and Biogen’s consummation of commercial player Apellis Pharmaceuticals. There were a total of seven deals of that magnitude in all of 2025. It’s no surprise. Large drugmakers are filling their late-stage pipelines to fend off patent cliffs, padding out earlier R&D engines to extend their dominance in certain fields and doubling down on emerging therapeutic classes.
Read the full article: Pharma’s $25.5B March Shopping Spree Sets up a Banner Year for M&A //
Source: https://endpoints.news/pharma-goes-on-25b-eight-day-acquisition-spree/